Form 4: Cytokinetics Director Edward M. Kaye Acquires Shares in Lieu of Cash Retainer
SEC Form 4 Filing
Director Edward M. Kaye acquired 228 shares of Cytokinetics Inc. common stock on July 1, 2024, as a stock award in lieu of a cash retainer payment.
Summary
- On July 1, 2024, Edward M. Kaye, a director of Cytokinetics Inc., acquired 228 shares of common stock.
- The acquisition was a stock award in lieu of a cash retainer payment.
- Following the transaction, Kaye directly owns 25,145 shares of Cytokinetics Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a stock award, which doesn't inherently indicate positive or negative sentiment.
Positives
- The director's decision to take stock in lieu of cash may signal confidence in the company's future prospects.
Industry Context
Directors receiving stock in lieu of cash compensation is a fairly common practice, especially in biotech companies, as it aligns their interests with those of shareholders.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it aligns the director's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of transaction: Edward M. Kaye acquired 228 shares of Cytokinetics Inc. common stock. |
| 07/03/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.